Form 10-Q Akebia Therapeutics, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Akebia Therapeutics (AKBA) Posts Q2 Loss of 40c/Share
August 11, 2015 4:33 PM EDTAkebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.40), $0.11 better than the analyst estimate of ($0.51).
For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.
... More